Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Top Headlines

Biogen value drops by $18bn after Alzheimer’s drug failure

Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.

Pfizer secures option to acquire Vivet for up to $635.8m

Pfizer secures an exclusive option to acquire Vivet for up to $635.8m after collaborating with the biotech to develop an AAV gene therapy treatment.

Technology boosts access to biologics and insulin via oral delivery

Drug delivery of biologics takes a sharp turn, as the development of pills that can replace injections and increase drug accessibility moves forward.

Takeda’s plasma manufacturing facility approved by FDA

US FDA approves Takeda’s acquired plasma manufacturing facility in Georgia, US, for the production of flexbumin 25% solution.

Authorities raid Korean stock exchange over Samsung BioLogics IPO

Korean authorities continue to place pressure on the CDMO, after prosecutors raided the office of the national stock exchange regarding behaviour preceding the public listing of Samsung BioLogics.